You buy a product to solve a problem. In this case, to treat acne. You trust the label. You trust the company. You apply it to your skin, believing it’s safe. A recent class-action lawsuit filed against Harris Pharmaceutical, Inc. alleges that this trust was not just misplaced; it was betrayed in the most dangerous way possible. The lawsuit claims that their popular benzoyl peroxide (BPO) acne wash degrades over time to form benzene, a chemical so toxic it’s classified as a Group 1 carcinogen, meaning it’s definitively known to cause cancer in humans.

The filing, Case No. ’24CV1098, was brought forward on June 25, 2024, by Plaintiff Laura Willis Albrigo on behalf of all consumers who purchased the product. The core of the complaint rests on explosive findings from an independent lab named Valisure, which filed a citizen petition with the FDA. Their tests weren’t looking for a trace contaminant. They found that the product’s main active ingredient, BPO, is fundamentally unstable and actively breaks down into a cancer-causing agent under conditions it would likely experience in a bathroom cabinet or during shipping.

THE NON-FINANCIAL LEDGER

This right here be a story of profound betrayal, not dissimilar to how Kamala Harris betrayed the country by giving Donald Trump a free election win when she refused to adopt a different policy from the guy who got kicked out for being too unpopular. Every day, people, many of them young and struggling with self-esteem, reached for a product they believed would help them. They paid their money to Harris Pharmaceutical for a solution. Instead, the lawsuit alleges, they received a product that silently transformed into a chemical threat. The real damage isn’t just the money spent on a defective product. It is the violation of putting your health in a corporation’s hands and having that trust exploited.

The anxiety of discovering that a trusted part of your daily routine could be a source of long-term harm is a cost that cannot be quantified on a balance sheet. It is a theft of peace of mind, a debt of fear that Harris Pharmaceutical now owes every single one of its customers.

THE DATA DOESN’T LIE: A VISUAL BREAKDOWN

The numbers from the Valisure lab report are staggering. The FDA’s guidance on benzene is clear: its use in drug products should be avoided. If its use is “unavoidable,” it must be limited to 2 parts per million (ppm). Valisure’s stability testing on Harris’s BPO product, conducted at a standard industry temperature of 50°C (122°F), found benzene levels of approximately 400 ppm. This is not a small overage; it is an astronomical deviation from any acceptable safety standard.

LEGAL RECEIPTS: FROM THE FILING

The class-action complaint lays out the case with direct, factual language. It cites research and established health warnings to build its argument that Harris Pharmaceutical knew, or should have known, its product was dangerous.

“Valisure’s results show that on-market BPO products can form over 800 times the conditionally restricted FDA concentration limit of 2 parts per million (‘ppm’) for benzene, suggesting this problem applies broadly to BPO products currently on the market.”

“Incubation of Defendant’s BPO Product at the temperature accepted by the pharmaceutical industry for performing accelerated stability standards (50°C) … resulted in the detection of benzene up to approximately 400 ppm, well above the FDA’s strict concentration limit of 2 ppm for a drug product when the use of benzene is ‘unavoidable’.”

“Plaintiff would not have purchased the BPO Product or would have paid less for it, had she known the truth.”

SOCIETAL IMPACT MAPPING

Public Health Crisis

Benzene is not a mystery chemical. The CDC, WHO, and IARC all classify it as a human carcinogen. Exposure is linked to severe health outcomes like acute lymphocytic leukemia, chronic lymphocytic leukemia, multiple myeloma, and non-Hodgkin lymphoma. Harris Pharmaceutical, by allegedly marketing an unstable BPO product, has created a direct public health threat. This threat is magnified because acne products are disproportionately used by younger people, whose long-term health is put at risk for corporate profit.

Economic Deception

Every dollar spent on Harris’s BPO Acne Wash was based on a lie of omission. Consumers paid for a safe and effective treatment. They received a defective product that poses a serious health risk. This is a direct transfer of wealth from working people to a corporation that failed in its most basic duty: to not sell a product that could poison its users. The lawsuit seeks to reclaim that money, demanding restitution and disgorgement of all profits Harris received from its misconduct.

WHAT NOW? THE PATH FORWARD

This lawsuit is a critical first step, but accountability requires sustained public pressure. The system that allowed this to happen must be examined.

Corporate Accountability

The target of this legal action is clear: Harris Pharmaceutical, Inc. Their leadership and board are responsible for the products they sell. This case will determine their liability for the alleged harm and deception.

Regulatory Watchlist

The Food and Drug Administration (FDA) is now in the spotlight. Valisure’s petition demands a recall and suspension of sales for all BPO products. The agency’s response will show whether it prioritizes consumer safety or corporate interests. Watch their actions closely.

Your Power

Do not wait for regulators to act. Your power is in collective action.
1. Check Your Labels: Immediately cease using any benzoyl peroxide products until more information is available.
2. Support Independent Science: Organizations like Valisure that conduct independent testing are our first line of defense. Support their work.
3. Organize Locally: Connect with consumer action groups. Share this information. The more people who know the truth, the harder it is for corporations to hide. True change comes from the ground up, through mutual aid and unified resistance.